Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

A novel benzo-heterocyclic amine derivative N30 inhibits influenza virus replication by depression of Inosine-5'-Monophospate Dehydrogenase activity.

Hu J, Ma L, Wang H, Yan H, Zhang D, Li Z, Jiang J, Li Y.

Virol J. 2017 Mar 15;14(1):55. doi: 10.1186/s12985-017-0724-6.

2.

Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators.

Mandal RS, Ta A, Sinha R, Theeya N, Ghosh A, Tasneem M, Bhunia A, Koley H, Das S.

Sci Rep. 2016 Dec 19;6:39454. doi: 10.1038/srep39454.

3.

Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN-augmenting activity in airway epithelium.

Porter JD, Watson J, Roberts LR, Gill SK, Groves H, Dhariwal J, Almond MH, Wong E, Walton RP, Jones LH, Tregoning J, Kilty I, Johnston SL, Edwards MR.

J Antimicrob Chemother. 2016 Oct;71(10):2767-81. doi: 10.1093/jac/dkw222. Epub 2016 Jul 25.

4.

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials.

Aminizadeh E, Alavian SM, Akbari Sari A, Ebrahimi Daryani N, Behnava B.

Hepat Mon. 2016 Mar 6;16(3):e28537. doi: 10.5812/hepatmon.28537. eCollection 2016 Mar. Review.

5.

Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.

Waldenström J, Westin J, Nyström K, Christensen P, Dalgard O, Färkkilä M, Lindahl K, Nilsson S, Norkrans G, Krarup H, Norrgren H, Rauning Buhl M, Stenmark S, Lagging M.

PLoS One. 2016 May 11;11(5):e0155142. doi: 10.1371/journal.pone.0155142. eCollection 2016.

6.

Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication.

Wang Y, Wang W, Xu L, Zhou X, Shokrollahi E, Felczak K, van der Laan LJ, Pankiewicz KW, Sprengers D, Raat NJ, Metselaar HJ, Peppelenbosch MP, Pan Q.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2834-48. doi: 10.1128/AAC.02700-15. Print 2016 May.

7.

Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever.

Oestereich L, Rieger T, Lüdtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Muñoz-Fontela C, Günther S.

J Infect Dis. 2016 Mar 15;213(6):934-8. doi: 10.1093/infdis/jiv522. Epub 2015 Nov 3.

8.

Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production.

Wang Y, McGivern DR, Cheng L, Li G, Lemon SM, Niu J, Su L, Reszka-Blanco NJ.

PLoS One. 2015 Aug 14;10(8):e0135232. doi: 10.1371/journal.pone.0135232. eCollection 2015.

9.

Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?

Karageorgopoulos DE, Allen J, Bhagani S.

World J Hepatol. 2015 Jul 28;7(15):1936-52. doi: 10.4254/wjh.v7.i15.1936. Review.

10.

HCV Kinetic Models and Their Implications in Drug Development.

Nguyen T, Guedj J.

CPT Pharmacometrics Syst Pharmacol. 2015 Apr;4(4):231-42. doi: 10.1002/psp4.28. Epub 2015 Apr 17. Review.

11.

Modelling hepatitis C therapy--predicting effects of treatment.

Perelson AS, Guedj J.

Nat Rev Gastroenterol Hepatol. 2015 Aug;12(8):437-45. doi: 10.1038/nrgastro.2015.97. Epub 2015 Jun 30. Review.

12.

Betulinic acid exerts anti-hepatitis C virus activity via the suppression of NF-κB- and MAPK-ERK1/2-mediated COX-2 expression.

Lin CK, Tseng CK, Chen KH, Wu SH, Liaw CC, Lee JC.

Br J Pharmacol. 2015 Jun 23. doi: 10.1111/bph.13233. [Epub ahead of print]

13.

Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro.

Teng L, Ding D, Chen Y, Dai H, Liu G, Qiao Z, An R.

Cancer Cell Int. 2014 Sep 3;14:63. doi: 10.1186/1475-2867-14-63. eCollection 2014.

14.

Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.

Satoh S, Mori K, Ueda Y, Sejima H, Dansako H, Ikeda M, Kato N.

PLoS One. 2015 Feb 20;10(2):e0118313. doi: 10.1371/journal.pone.0118313. eCollection 2015.

15.

Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors.

Yeo KL, Chen YL, Xu HY, Dong H, Wang QY, Yokokawa F, Shi PY.

Antimicrob Agents Chemother. 2015 Apr;59(4):2086-93. doi: 10.1128/AAC.04779-14. Epub 2015 Jan 26.

16.

Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model.

Carpentier A, Tesfaye A, Chu V, Nimgaonkar I, Zhang F, Lee SB, Thorgeirsson SS, Feinstone SM, Liang TJ.

J Clin Invest. 2014 Nov;124(11):4953-64. doi: 10.1172/JCI75456. Epub 2014 Oct 8.

17.

Inhibition of enterovirus 71 by adenosine analog NITD008.

Deng CL, Yeo H, Ye HQ, Liu SQ, Shang BD, Gong P, Alonso S, Shi PY, Zhang B.

J Virol. 2014 Oct;88(20):11915-23. doi: 10.1128/JVI.01207-14. Epub 2014 Aug 6.

18.

Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.

Rehermann B, Bertoletti A.

Hepatology. 2015 Feb;61(2):712-21. doi: 10.1002/hep.27323. Review.

19.

HCV infection treatment: a future full of hope.

Amiri M, Kiahashemi K.

Gastroenterol Hepatol Bed Bench. 2013 Winter;6(1):1-5. No abstract available.

20.

PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.

Markova AA, Mihm U, Schlaphoff V, Lunemann S, Filmann N, Bremer B, Berg T, Sarrazin C, Zeuzem S, Manns MP, Cornberg M, Herrmann E, Wedemeyer H.

PLoS One. 2014 Apr 21;9(4):e94512. doi: 10.1371/journal.pone.0094512. eCollection 2014.

Supplemental Content

Support Center